Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Skyhawk-ClinicalTrial

More Like This

PR Newswire associated0

Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease

PR Newswire associated0

Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease

PR Newswire associated0

Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease

PR Newswire associated0

Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease

PR Newswire associated0

Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom

PR Newswire associated0

Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway

PR Newswire associated0

Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington's Disease